Table 4.
Univariate and Multivariate Analyses of NLR and PLR in Overall Survival and Progression-Free Survival
| Overall survival | Progression-free survival | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||||
| UVA | MVA | UVA | MVA | |||||||||
|
|
|
|
|
|||||||||
| HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age (≤64 vs >64) | 1.26 | 1.04–1.54 | 0.021 | 1.19 | 0.97–1.45 | 0.09 | 1.18 | 0.98–1.43 | 0.08 | |||
| Sex (female vs male) | 1.33 | 1.09–1.63 | 0.006 | 1.25 | 1.03–1.52 | 0.025 | ||||||
| ECOG | 0.038 | 0.033 | 0.559 | |||||||||
| ECOG (ECOG 2 vs 0) | 0.39 | 0.19–0.80 | 0.011 | 0.4 | 0.19–0.84 | 0.016 | 0.7 | 0.34–1.43 | 0.327 | |||
| ECOG (ECOG 2 vs 1) | 0.42 | 0.21–0.85 | 0.016 | 0.48 | 0.24–0.98 | 0.046 | 0.75 | 0.37–1.52 | 0.422 | |||
| Pathology | 0.001 | 0.002 | 0.001 | |||||||||
| Pathology (adenoca vs adenoSCCa) | 0.91 | 0.69–1.19 | 0.494 | 0.8 | 0.61–1.06 | 0.129 | 0.58 | 0.22–1.58 | 0.29 | |||
| Pathology (adenoca vs PD) | 0.73 | 0.27–1.02 | 0.55 | 0.51 | 0.18–1.43 | 0.203 | 5.59 | 2.29–13.64 | <0.001 | |||
| Subsite (head vs other) | 1.16 | 0.94–1.43 | 0.18 | 1.2 | 0.98–1.47 | 0.08 | ||||||
| T stage | 0.051 | 0.47 | ||||||||||
| (T1 vs T2) | 0.34 | 0.13–0.93 | 0.035 | 0.52 | 0.21–1.26 | 0.15 | ||||||
| (T1 vs T3) | 0.99 | 0.67–1.46 | 0.97 | 0.9 | 0.61–1.31 | 0.57 | ||||||
| (T1 vs T4) | 0.81 | 0.66–1.00 | 0.052 | 1.02 | 0.83–1.24 | 0.88 | ||||||
| N stage (N0 vs N1) | 0.99 | 0.81–1.21 | 0.9 | 1.05 | 0.87–1.27 | 0.63 | ||||||
| Size (≤3.1 vs >3.1) | 1.41 | 1.16–1.73 | 0.001 | 1.35 | 1.09–1.66 | 0.005 | 1.4 | 1.16–1.70 | <0.001 | 1.39 | 1.15–1.69 | 0.001 |
| Resectability (unresectable vs borderline) | 0.62 | 0.48–0.80 | <0.001 | 0.62 | 0.47–0.81 | 0.001 | 0.83 | 0.66–1.04 | 0.106 | |||
| Chemotherapy (gemcitabine vs not gemcitabine) | 1.03 | 0.84–1.26 | 0.783 | 1.17 | 0.97–1.42 | 0.098 | ||||||
| CA 19-9 (≤304.5 vs >304.5) | 1.35 | 1.11–1.64 | 0.003 | 1.32 | 1.08–1.61 | 0.006 | 1.38 | 1.14–1.67 | 0.001 | 1.35 | 1.11–1.63 | 0.002 |
| NLR and PLR group | 0.001 | 0.001 | <0.001 | <0.001 | ||||||||
| Group C vs group A | 0.60 | 0.46–0.79 | <0.001 | 0.62 | 0.47–0.81 | 0.001 | 0.61 | 0.47–0.79 | <0.001 | 0.63 | 0.49–0.82 | 0.001 |
| Group C vs group B | 0.82 | 0.65–1.02 | 0.072 | 0.73 | 0.58–0.91 | 0.007 | 0.75 | 0.61–0.93 | 0.009 | 0.69 | 0.56–0.86 | 0.001 |
NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; UVA, univariate analysis; MVA, multivariate analysis; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; SCCa, squamous cell carcinoma; PD, poorly differentiated.